Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SGN-B6A |
Synonyms | |
Therapy Description |
SGN-B6A is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting integrin beta-6 linked to monomethyl auristatin E, which delivers the anti-microtubule agent to integrin beta-6-expressing tumor cells, potentially resulting in inhibition of tumor growth (PMID: 37619980). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SGN-B6A | SGN B6A|SGNB6A|anti-integrin beta-6/MMAE ADC SGN-B6A | SGN-B6A is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting integrin beta-6 linked to monomethyl auristatin E, which delivers the anti-microtubule agent to integrin beta-6-expressing tumor cells, potentially resulting in inhibition of tumor growth (PMID: 37619980). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04389632 | Phase I | SGN-B6A | A Study of SGN-B6A in Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | CHE | 1 |